Mirati Therapeutics (MRTX) Tops Q4 EPS by 6c

Mirati Therapeutics (NASDAQ: MRTX) reported Q4 EPS of ($0.77), $0.06 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance